🔗 Share this article The United States and United Kingdom Reach No-Tariff Agreement on Prescription Drugs. Conceptual image of medicine trade. Britain and America have hammered out a major commercial pact that will maintain no import taxes on British medicine exports entering the US market. Agreement Details of the Deal As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move guarantees that import taxes on these vital products will be held at nothing for a timeframe of 36 months. This deal comes after previous warnings to hike tariffs on branded pharmaceutical imports, with figures floated up to double the cost. "This arrangement between the Britain bolsters the global environment for cutting-edge drugs and brings much-needed equity to transatlantic medicine commerce," a statement noted. Commercial Importance Pharmaceuticals are one of the UK's biggest exports to the US, which is clearly the biggest buyer for large British pharmaceutical firms. Export figures show that in the one-year period prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for 17.4% of all goods exports in that span. "This deal protects employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented. Specific UK Commitments The pact includes several key pledges from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent. Higher Drug Budget: There is a goal to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade. Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments exceeded 20%. Broader Context The pact comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and regulatory access. These tensions were exacerbated by arguments that American customers were charged significantly more for the identical medicines than patients in the other developed nations. Recently, several significant manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been pledged toward US facilities. One official stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
Conceptual image of medicine trade. Britain and America have hammered out a major commercial pact that will maintain no import taxes on British medicine exports entering the US market. Agreement Details of the Deal As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move guarantees that import taxes on these vital products will be held at nothing for a timeframe of 36 months. This deal comes after previous warnings to hike tariffs on branded pharmaceutical imports, with figures floated up to double the cost. "This arrangement between the Britain bolsters the global environment for cutting-edge drugs and brings much-needed equity to transatlantic medicine commerce," a statement noted. Commercial Importance Pharmaceuticals are one of the UK's biggest exports to the US, which is clearly the biggest buyer for large British pharmaceutical firms. Export figures show that in the one-year period prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for 17.4% of all goods exports in that span. "This deal protects employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented. Specific UK Commitments The pact includes several key pledges from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent. Higher Drug Budget: There is a goal to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade. Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments exceeded 20%. Broader Context The pact comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and regulatory access. These tensions were exacerbated by arguments that American customers were charged significantly more for the identical medicines than patients in the other developed nations. Recently, several significant manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been pledged toward US facilities. One official stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.